申请人:Boechat Nubia
公开号:US20090054501A1
公开(公告)日:2009-02-26
This invention refers to new 1,2,3-triazole and imidazole compounds included in the families of compounds represented by general formula VIII.
where: X is an atom of “C” or “N;” where X is “N” the radicals do triazole ring are represented by: R
1
=COR
2
, CSR
3
, CN(R
4
)R
5
or CF
2
R
6
; R
2
=H, NHNH
2
, alkyl, aryl substituted or not, OH, NR
7
R
8
or OR
9
; R
3
=alkyl or aryl substituted or not; R
4
=H, OH, alkyl or aryl substituted or not; R
5
=R
6
=R
7
=R
8
=R
9
=R
10
=H, alkyl or aryl substituted or not; where X is “C” the radicals do imidazolic ring are represented by: R
1
=COR
2
; R
2
=NHNH
2
, OH, OR
3
, or NR
4
R
5
; R
3
=alkyl or aryl substituted or not; =R
5
H, alkyl or aryl substituted or not; R
10
=NHR
6
or NR
6
R
7
; R
6
=R
7
=COR
8
; R
8
=aryl substituted or not; while radical R
n
can be located in any one or in more than one of the carbon atoms of the aromatic ring, and these radicals can be equal or different, represented by hydrogen, alkylic groups with 1 or more carbon atoms in a linear or branched chain alkenes or alkynes, hydroxyl, hydroxyalkyl or oxygenated functions in acyclic or cyclic systems forming an heterocyclic ring, free or substituted amines, thioalkyl, donators and/or removing groupings of electrons or halogens, thus “n” can vary from 1 to 5. This invention also refers to a pharmaceutical composition comprising, as active principle, at least one of the azole compounds represented by the general formula VIII, to the use of such compositions and to method of treatment or inhibition de tuberculosis and leishmaniasis.
本发明涉及新的1,2,3-三唑和咪唑化合物,这些化合物属于由通式VIII表示的化合物家族,其中:X是“C”或“N”的原子;当X为“N”时,三唑环的基团表示为:R1=COR2、CSR3、CN(R4)R5或CF2R6;R2=H、NHNH2、烷基、芳基取代或不取代、OH、NR7R8或OR9;R3=烷基或芳基取代或不取代;R4=H、OH、烷基或芳基取代或不取代;R5=R6=R7=R8=R9=R10=H、烷基或芳基取代或不取代;当X为“C”时,咪唑环的基团表示为:R1=COR2;R2=NHNH2、OH、OR3或NR4R5;R3=烷基或芳基取代或不取代;=R5H、烷基或芳基取代或不取代;R10=NHR6或NR6R7;R6=R7=COR8;R8=芳基取代或不取代;而基团Rn可以位于任何一个或多个芳香环的碳原子上,这些基团可以相等或不同,由氢、线性或支链烷基链上具有1个或多个碳原子的烷基基团、烯烃或炔烃、羟基、羟基烷基或在无环或环形系统中含氧杂环的功能、自由或取代的胺、硫代烷基、电子给体和/或电子受体基团或卤素表示,因此“n”可以从1到5变化。本发明还涉及一种制药组合物,其包含至少一种由通式VIII表示的唑类化合物作为活性成分,以及使用这种组合物的方法和治疗或抑制结核病和利什曼病的方法。